AZN:NYSE
AstraZeneca PLC (US)
$159.20
arrow_upward
+0.26%(+0.42) 1D
$159.20
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$159.45
High
$160.06
Low
$158.53
Mkt. cap
244.31B
Avg. vol.
2.92M
Volume
2.12M
Dividend
2.02%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
23.80
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
Open
$159.45
High
$160.06
Low
$158.53
Mkt. cap
244.31B
Avg. vol.
2.92M
Volume
2.12M
Dividend
2.02%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
23.80
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Zacks
·
12 hours ago
Cancer Stocks to Consider as Oncology Innovation Accelerates
AD HOC NEWS
·
13 hours ago
AstraZeneca stock trades at EUR 142.88 with 362,423 shares versus 3,369,364 average
Traders Union
·
19 hours ago
AstraZeneca stock price prediction: GBX11,694 support under pressure
Kalkine Media
·
20 hours ago
Why Are AstraZeneca (LSE:AZN) Shares Edging Lower After The Summit Therapeutics Investment Today?
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com